|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
Rejuve.AI's Longevity Ecosystem Powers Up with Crypto Adoption
Apr 08, 2024 at 11:30 pm
Longevity research platform Rejuve.AI has announced partnerships with GlycanAge, Vita Authentica, and Peptide Bioregulator, enabling consumers to purchase their products using the RJV crypto token. These partnerships allow individuals to monetize their health data through Rejuve.AI's Longevity App while contributing to longevity research by providing valuable data for the development of new therapies and treatments.

Rejuve.AI's Longevity Ecosystem Expands with Crypto Payment Adoption
SINGULARITYNET'S HEALTHCARE FORAY GAINS MOMENTUM
San Francisco, California - Rejuve.AI, a pioneering longevity AI company operating within the SingularityNET ecosystem, has announced a groundbreaking partnership with three prominent consumer health brands: GlycanAge, Vita Authentica, and Peptide Bioregulator. This collaboration marks a transformative step towards democratizing longevity research and healthy aging through the integration of blockchain and AI.
The three partner brands will now accept Rejuve.AI's native cryptocurrency, RJV, as payment for their products and services. This move not only enhances the accessibility of personalized longevity solutions but also contributes significantly to the burgeoning longevity sector.
REJUVENATING LONGEVITY RESEARCH THROUGH DECENTRALIZATION
Rejuve.AI's decentralized longevity research platform empowers individuals to share their medical, lifestyle, and biological data. Leveraging AI's transformative capabilities, the platform translates this vast data into actionable insights that guide personalized longevity strategies.
The Longevity App, developed by Rejuve.AI, provides a comprehensive platform for users to submit their health data from various sources, including surveys, lab results, and wearable devices. In return for sharing their valuable health information, users receive RJV tokens redeemable for products and services offered by Rejuve.AI's partner brands.
This data-sharing mechanism not only monetizes users' health data but also fuels the advancement of longevity research. The data collected through the Longevity App contributes to the development of new drugs, therapies, and treatments, ultimately benefiting humanity's pursuit of healthier and longer lives.
REJUVENATING TREATMENT DEVELOPMENT THROUGH BIOLOGICAL INSIGHTS
Rejuve.Bio, a fellow SingularityNET company, capitalizes on the insights generated by Rejuve.AI to develop and commercialize innovative experimental therapies. The partnership with consumer health brands like GlycanAge, Vita Authentica, and Peptide Bioregulator further strengthens Rejuve.Bio's efforts to bring transformative longevity solutions to market.
EMBRACING THE VALUE OF LONGEVITY RESEARCH
The decision by GlycanAge, Vita Authentica, and Peptide Bioregulator to accept RJV tokens reflects their unwavering belief in the transformative power of longevity research.
"We are thrilled to see the industry recognizing the crucial role that crypto plays in healthcare and longevity research," said Jasmine Smith, CEO of Rejuve.AI. "Our partnership with these leading brands demonstrates our commitment to realizing our mission of pioneering groundbreaking longevity research and innovation."
CONCLUSION
The integration of RJV crypto tokens into the offerings of GlycanAge, Vita Authentica, and Peptide Bioregulator marks a significant milestone in the advancement of longevity research. This collaboration opens new avenues for funding, incentivizing data sharing, and fostering innovation within the longevity sector. As the adoption of RJV tokens expands, Rejuve.AI and its partners continue to reshape the future of healthy aging, empowering individuals and researchers alike to unlock the potential of a longer, healthier life.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
- Consensus 2026 Miami: Web3, Blockchain, Cryptocurrency, NFTs, Metaverse, Conference, May 5th — Where Wall Street Meets the Digital Frontier
- May 01, 2026 at 11:27 pm
- Miami buzzes as Consensus 2026 approaches on May 5th, highlighting Web3, blockchain, crypto, NFTs, and the metaverse's shift from hype to institutional and sustainable reality.
-
-
- Bitcoin Miners Electrify the Grid: Ohio Gas Plant Acquisition Powers Up a New Era for Digital Gold
- Apr 30, 2026 at 10:38 pm
- The Bitcoin mining industry is undergoing a significant transformation, with major players aggressively expanding operations and strategically acquiring energy assets like Ohio gas plants to solidify their future in the digital economy.
-
-
- Solana's Slippery Slope: Price Prediction Points to Resistance Loss and Potential Further Drops
- Apr 30, 2026 at 09:08 pm
- Solana is struggling to break key resistance, signaling potential downside. Repeated rejections at $86-$88, coupled with a broken short-term pattern, point to targets as low as $67, or even $40, as sellers maintain control. Investors should watch critical support levels closely.
-
-
- NYC's New Beat: Staking Systems, USD1, and Governance Drive Crypto's Next Wave
- Apr 30, 2026 at 03:02 pm
- From lucrative USD1 earning events to robust governance models, the crypto sphere is buzzing with innovations reshaping how we engage with digital assets, focusing on long-term commitment and stablecoin utility.
-
- OKX Unveils Agent Payments Protocol: Ushering in a New Era of AI Transactions
- Apr 30, 2026 at 02:53 pm
- OKX launches its Agent Payments Protocol (APP), an open standard for AI-driven commerce, enabling agents to manage full business cycles. Explore the implications for AI transactions and agentic payments.

































